CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-26 | Bhavnagri Veer General Counsel | Grant or award | +22,202 | 421,353 | ||
| 2021-03-26 | Bhavnagri Veer General Counsel | Grant or award · Stock Option (Right to Buy) | +82,469 | 82,469 | ||
| 2021-03-26 | MOORE ALISON Chief Technical Officer | Grant or award | +24,866 | 127,440 | ||
| 2021-03-26 | MOORE ALISON Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +92,365 | 92,365 | ||
| 2021-03-26 | SCHMIDT ERIC THOMAS Chief Financial Officer | Grant or award | +24,866 | 96,097 | ||
| 2021-03-26 | SCHMIDT ERIC THOMAS Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +92,365 | 92,365 | ||
| 2021-03-26 | Amado Rafael EVP of R&D and CMO | Grant or award | +24,866 | 134,901 | ||
| 2021-03-26 | Amado Rafael EVP of R&D and CMO | Grant or award · Stock Option (Right to Buy) | +92,365 | 92,365 | ||
| 2021-03-15 | Bhavnagri Veer General Counsel | Option exercise | +10,000 | $2.27 | $23K | 415,774 |
| 2021-03-15 | Bhavnagri Veer General Counsel | Sale | −6,623 | $38.16 | $253K | 409,151 |
| 2021-03-15 | Bhavnagri Veer General Counsel | Sale | −9,600 | $37.79 | $363K | 399,551 |
| 2021-03-15 | Bhavnagri Veer General Counsel | Sale | −400 | $38.15 | $15K | 399,151 |
| 2021-03-15 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −10,000 | 152,300 | ||
| 2021-03-15 | Amado Rafael EVP of R&D and CMO | Sale | −2,798 | $38.05 | $106K | 110,035 |
| 2021-03-15 | Chang David D President and CEO | Sale | −20,513 | $38.57 | $791K | 2,204,417 |
| 2021-03-15 | MOORE ALISON Chief Technical Officer | Sale | −6,164 | $38.14 | $235K | 102,574 |
| 2021-03-15 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −8,053 | $38.23 | $308K | 71,231 |
| 2021-01-15 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −3,547 | $31.69 | $112K | 1,164,048 |
| 2021-01-15 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −11,053 | $32.40 | $358K | 1,152,995 |
| 2021-01-15 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −400 | $33.29 | $13K | 1,152,595 |
Page 13 of 18 · 348 trades